Physician profile
Mary Dene
NPI 1669411849
$2,233.59
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $908 · 2021: $1,212 · 2022: $113.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $434.28 | 2020-2022 | |
| Novo Nordisk INC | $298.22 | 2020-2022 | |
| Allergan, INC. | $187.21 | 2020-2021 | |
| Amarin Pharma, INC. | $147.53 | 2020 | |
| Pfizer INC. | $113.04 | 2020-2021 | |
| Antares Pharma, INC. | $108.39 | 2020-2021 | |
| Mylan Specialty L.P. | $99.71 | 2020-2021 | |
| Lilly USA, LLC | $81.62 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $79.49 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $78.97 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.74 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $68.81 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.92 | 2020-2021 | |
| Avanir Pharmaceuticals, INC. | $46.26 | 2021 | |
| Amgen INC. | $44.56 | 2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $42.52 | 2021 | |
| Neurocrine Biosciences, INC. | $37.59 | 2022 | |
| Sunovion Pharmaceuticals INC. | $32.90 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $32.05 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $29.71 | 2020-2021 | |
| Currax Pharmaceuticals LLC | $28.84 | 2021 | |
| Eisai INC. | $24.73 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.92 | 2021 | |
| Nestle Healthcare Nutrition INC. | $19.33 | 2021 | |
| Astellas Pharma US INC | $16.67 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $16.54 | 2021 | |
| Lundbeck LLC | $14.04 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Dene listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.